MammaPrint and BluePrint Testing for Breast Cancer
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Recruiting
Observational Study
Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 30,000 (estimated)
- Sponsor
- Agendia · Industry
Who this trial is looking for
This trial is looking for patients with stage I to III breast cancer who are receiving MammaPrint® and BluePrint testing. By joining, you will help researchers gather more information and possibly open up more study options in the future.
Are You a Good Fit for This Trial?
You may be able to join if
- I have stage I, II, or III breast cancer
- I will be getting MammaPrint testing
- I will be getting BluePrint testing
- I have signed the informed consent form
- I have a new primary tumor
You may not be able to join if
- My tumor sample has less than 30% tumor cells
- I have metastatic disease
- I have recurrent disease
- I have stage 0 disease
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive de…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Stage I, II, or III patients who receive MammaPrint, with or without BluePrint testing (male or female)
* Informed consent form signed on the same day or before enrollment
* New primary lesion
Exclusion Criteria:
* Tumor sample shipped to Agendia with ≤ 30% tumor cells or th…
Contacts